What are resistance rates to fluoroquinolones in the treatment of chronic bacterial prostatitis (CBP)?

Updated: Jan 15, 2019
  • Author: Samantha D Kraemer, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

Fluoroquinolone therapy is not always feasible in patients with contraindications such as long QT syndrome or tendonitis. Reported resistance rates to fluoroquinolones in Enterobacteriaceae causing urinary tract or intra-abdominal infections have increased in previous years and exceed 50% in some parts of the world, especially Asia. In Europe and North America, resistance rates range from less than 10% in rural areas to more than 30% in sexual networks. [41]

National and international antibiotic stewardship practices have helped to lower the percentage of ciprofloxacin-resistant extended-spectrum β-lactamase (ESBL) Enterobacteriaceae in urinary isolates in both hospital and community settings. [42] Nevertheless, alternative antibiotics for treating CBP are needed.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!